During the past decade, Korea University Guro Hospital; Oncology conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 4 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Korea University Guro Hospital; Oncology" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Bukwang Pharmaceutical" with 2 trials sponsored, "Gangnam Severance Hospital" with 2 trials sponsored, "PharmaKing" with 2 trials sponsored and "AVEO Pharmaceuticals, Inc." with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Korea University Guro Hospital; Oncology" #1 collaborator was "Biodesix, Inc." with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Myung In Pharmaceutical Company" with 1 trials as a collaborator, "SAMJIN PHARM" with 1 trials as a collaborator and "Yonsei University" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Korea University Guro Hospital; Oncology" are "Breast Cancer" (2 trials), "Hepatitis B" (2 trials), "Non-small Cell Lung Cancer" (2 trials), "Acute Ischemic Stroke" (1 trials) and "Atherosclerosis" (1 trials). Many other conditions were trialed in "Korea University Guro Hospital; Oncology" in a lesser frequency.

Most popular intervention types in "Korea University Guro Hospital; Oncology" are "Drug" (11 trials), "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Trastuzumab" (2 trials), "ALLO-ASC-DFU" (1 trials), "Alectinib" (1 trials) and "Capecitabine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Korea University Guro Hospital; Oncology" are 12 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Korea University Guro Hospital; Oncology". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Korea University Guro Hospital; Oncology, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Korea University Guro Hospital; Oncology, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".